Duchem Bio Sees 16.3% Revenue Jump in First Half Driven by Diagnostic Agent Sales

Duchem Bio, a company specializing in radiopharmaceuticals, has announced a significant increase in its first-half financial performance, driven by strong sales of its diagnostic agents.

The company reported a total revenue of 20.9 billion won for the first half of the year, marking a 16.3% rise compared to the same period last year. This growth trajectory also extended to its operating profit, which increased by 24.6% to reach 3.2 billion won.

Duchem Bio attributed its robust performance primarily to the expanded sales of three key diagnostic agents. These agents are used for the detection of Alzheimer's disease, Parkinson's disease, and prostate cancer, indicating a growing demand for advanced diagnostic tools in these critical healthcare areas.

The company's success highlights the increasing market for specialized medical diagnostics, particularly in the fields of neurodegenerative diseases and oncology. Duchem Bio's focus on developing and distributing these advanced diagnostic solutions appears to be paying off, positioning it for continued growth.